Rate of growth in melanomas: Characteristics and associations of rapidly growing melanomas

Archives of Dermatology

Volumn 142, Issue 12, 2006, Pages 1551-1558

  Liu, Wendy ^a,b,c   Dowling, John P ^a   Murray, William K ^b   McArthur, Grant A ^b,c   Thompson, John F ^d   Wolfe, Rory ^e   Kelly, John W ^a  

^a ALFRED HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; CANCER GROWTH; CANCER INVASION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; INTERVIEW; LENTIGO; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; MELANOMA; PRIORITY JOURNAL; REVIEW; SKIN EXAMINATION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SKIN NEOPLASMS;

EID: 33845689183     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.12.1551     Document Type: Review

References (25)

1. Clark WH, From L, Bernardino EA, et al. The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705-726.
2. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498.
3. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
4. Talve LA, Collan YU, Ekfors TO. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin. J Cutan Pathol. 1996;23:335-343.
5. Florenes VA, Faye RS, Maelandsmo GM, et al. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res. 2000;6:3614-3620.
6. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res. 2000;6:1845-1853.
7. Florenes VA, Maelandsmo GM, Kerbel RS, et al. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol. 1998;153:305-312.
8. Grob JJ, Richard MA, Gouvernet J, et al. The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study. Int J Cancer. 2002;102:34-38.
9. Richard MA, Grob JJ, Avril MF, et al. Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol. 1999;135:269-274.
10. Kelly JW, Crutcher WA, Sagebiel RW. Clinical diagnosis of dysplastic melanocytic nevi: a clinicopathologic correlation. J Am Acad Dermatol. 1986;14:1044-1052.
11. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124:869-871.
12. Friedman RJ, Rigel DS, Kopf AW, et al. Volume of malignant melanoma is superior to thickness as a prognostic indicator: preliminary observation. Dermatol Clin. 1991;9:643-648.
13. Lipsker DM, Hedelin G, Heid E, et al. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch Dermatol. 1999;135:1451-1456.
14. Armstrong BK, Kricker A. Cutaneous melanoma. Cancer Surv. 1994;19:219-239.
15. Buettner PG, Leiter U, Eigentler TK, et al. Development of prognostic factors and survival in cutaneous melanoma over 25 years: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer. 2005;103:616-624.
16. Kelly JW. Melanoma in the elderly: a neglected public health challenge. Med J Aust. 1998;169:403-404.
17. Green A, MacLennan R, Youl P, et al. Site distribution of cutaneous melanoma in Queensland. Int J Cancer. 1993;53:232-236.
18. Hanrahan PF, Hersey P, Menzies SW, et al. Examination of the ability of people to identify early changes of melanoma in computer-altered pigmented skin lesions. Arch Dermatol. 1997;133:301-311.
19. Clark WH Jr, Elder DE, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904.
20. English DR, Heenan PJ, Holman CD, et al. Melanoma in Western Australia in 1980-81: incidence and characteristics of histological types. Pathology. 1987;19:383-392.
21. Australian Institute of Health and Welfare Web site http://www.aihw.gov. au. Accessed October 17, 2006.
22. Chamberlain AJ, Fritschi L, Giles GG, et al. Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol. 2002;138:609-614.
23. Holman CD, Armstrong BK. Pigmentary traits, ethnic origin, benign nevi, and family history as risk factors for cutaneous malignant melanoma. J Natl Cancer Inst. 1984;72:257-266.
24. Marks R, Dorevitch AP, Mason G. Do all melanomas come from "moles"? a study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol. 1990;31:77-80.
25. Chamberlain AJ, Fritschi L, Kelly JW. Nodular melanoma: patients' perceptions of presenting features and implications for earlier detection. J Am Acad Dermatol. 2003;48:694-701.